Skip to main content
Log in

Pancreatic secretory trypsin inhibitor in human Brunner's glands

  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Brunner's glands (duodenal glands) in humans are located mainly in the two proximal thirds of the duodenum. They are known to produce and secrete mucin. In recent years, human Brunner's glands have also been shown to express immunoreactivity toward epidermal growth factor-urogastrone (EGF-uro) and lysozyme. These proteins are considered to have a protective function within the gastrointestinal canal. Human pancreatic secretory trypsin inhibitor (PSTI) was recently identified in Brunner's glands. This present study was done by an immunohistochemical method, using monospecific polyclonal antibodies against human PSTI and human lysozyme, respectively. McManus/Alcian blue mucin staining was used to clarify the distribution of mucin. We found immunoreactive PSTI (irPSTI) in seven out of ten specimens. Lysozyme and mucin were present in all ten. While virtually all cells were stained for lysozyme and mucin, irPSTI was restricted to separate lobules and to cells in the ducts.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Kazal LA, Spicer DS, Brahinsky RA. Isolation of a crystalline trypsin inhibitor-anticoagulant protein from pancreas. J Am Chem Soc 1948;70:3034–3040.

    Google Scholar 

  2. Fritz H, Hüller I, Wiedemann M, Werle E. Zur Chemie und Physiologie der spezifischen Trypsininhibitoren aus den Bauchspecheldrusen von Rind, Hund, Schwein und Mensch. Hoppe-Seyler's Z Physiol Chem 1967;348:405–418.

    Google Scholar 

  3. Matsuda K, Ogawa M, Murata A, et al. Elevation of serum immunoreactive pancreatic secretory trypsin inhibitor contents in various malignant diseases. Res Commun Chem Pathol Pharmacol 1983;40:301–305.

    Google Scholar 

  4. Borgström A, Wehlin L. Correlation between serum concentrations of three specific exocrine pancreatic proteins and pancreatic duct morphology at ERCP examinations. Scand J Gastroenterol 1984;19:220–227.

    Google Scholar 

  5. Bohe M. Immunoreactive pancreatic secretory trypsin inhibitor in sera from patients with acute ulcerative colitis. Res Exp Med 1987;187:55–58.

    Google Scholar 

  6. Lasson Å, Borgstrom A, Ohlsson K. Elevated PSTI levels during severe inflammatory disease, renal insufficiency and after different surgical procedures. Scand J Gastroenterol 1986;21:1275–1280.

    Google Scholar 

  7. Matsuda K, Ogawa M, Shibata T. Postoperative elevation of serum pancreatic secretory trypsin inhibitor. Am J Gastroenterol 1985;80:694–698.

    Google Scholar 

  8. Shibata T, Ogawa M, Takata N, et al. Elevation of serum pancreatic secretory trypsin inhibitor following serious injury. Resuscitation 1988;16:163–168.

    Google Scholar 

  9. Halila H, Huhtala ML, Schröder T, et al. Pancreatic secretory trypsin-like immunoreactivity in pancreatectomized patients. Clin Chim Acta 1985;153:209–216.

    Google Scholar 

  10. Huhtala M-L, Pesonen K, Kalkkinen N, Stenman U-H. Purification and Characterization of a tumor-associated trypsin inhibitor from the urine of patient with ovarian cancer. J Biol Chem 1982;257:13713–13716.

    Google Scholar 

  11. Halila H, Huhtala M-L, Haglund C, et al. Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA125 and CEA. Br J Cancer 1987;56:153–156.

    Google Scholar 

  12. Bohe M, Lindstrom CG, Ohlsson K. Varying occurrence of gastroduodenal immunoreactive pancreatic secretory trypsin inhibitor. J Clin Pathol 1987;40:1345–1348.

    Google Scholar 

  13. Bohe M, Lindstrom C, Ohlsson K. Immunoreactive pancreatic secretory trypsin inhibitor in gastrointestinal mucosa. Adv Exp Med Biol 1988;240:101–105.

    Google Scholar 

  14. Freeman TC, Playford RJ, Quinn C, et al. Pancreatic secretory trypsin inhibitor in gastrointestinal mucosa and gastric juice. Gut 1990;31:1318–1323.

    Google Scholar 

  15. Bohe M, Borgstrom A, Lindstrom C, Ohlsson K. Pancreatic endoproteases and pancreatic secretory trypsin inhibitor immuno-reactivity in human Paneth cells. J Clin Pathol 1986;39:786–793.

    Google Scholar 

  16. Fukayama M, Hayashi Y, Koike M, et al. Immunohistochemical localization of pancreatic secretory trypsin inhibitor in fetal and adult pancreatic and extrapancreatic tissues. J Histochem Cytochem 1986;34:227–235.

    Google Scholar 

  17. Higashiyama M, Monden T, Ogawa M, et al. Immunohistochemical study on pancreatic secretory trypsin inhibitor (PSTI) in gastric carcinomas. Am J Clin Pathol 1990;93:8–13.

    Google Scholar 

  18. Bohe H, Bohe M, Lindström C, Ohlsson K. Immunohistochemical demonstration of pancreatic secretory trypsin inhibitor in normal and neoplastic colonic mucosa. J Clin Pathol 1990;43:901–904.

    Google Scholar 

  19. Bohe H, Bohe M, Lindstrom C, Ohlsson K. Immunoreactive pancreatic secretory trypsin inhibitor in normal, inflammatory and neoplastic gallbladders. Gastroenterol Jpn 1991;26:95–98.

    Google Scholar 

  20. Ogawa M, Tsushima T, Ohba Y, et al. Stimulation of DNA synthesis in human fibroblasts by human pancreatic secretory trypsin inhibitor. Res Commun Chem Pathol Pharm 1985;50:155–158.

    Google Scholar 

  21. Freeman TC, Curry B, Calam J, Woodburn J. Pancreatic secretory trypsin inhibitor stimulates the growth of rat pancreatic carcinoma cells. Gastroenterology 1990;99:1414–1420.

    Google Scholar 

  22. McKeehan WL, Sakagami Y, Hoshi H, McKeehan K. Two apparent human endothelial cell growth factors from human hepatoma cells are tumor-associated proteinase inhibitors. J Biol Chem 1986;261:5378–5383.

    Google Scholar 

  23. Sternberger LA, Hardy PH Jr, Cuculis JJ, Meyer HG. The unlabelled antibody enzyme method of immunochemistry. Preparations and properties of soluble antigen-antibody complex (horseradish peroxidase-antihorseradish peroxidase) and its use in identification of spirochetes. J Histochem Cytochem 1970;18:315–333.

    Google Scholar 

  24. Fryksmark U, Ohlsson K, Polling Å, Tegner H. Distribution of antileukoprotease and characterization of human antileukoprotease in serum. Ann Otol Rhinol Laryngol 1982;91:268–271.

    Google Scholar 

  25. Eddeland A, Ohlsson K. Purification and immunochemical quantitation of human pancreatic secretory trypsin inhibitor. Scand J Clin Lab Invest 1978;38:261–267.

    Google Scholar 

  26. Kittas C, Aroni K, Kotsis L, Papadimitriou S. Distribution of lysozyme, al-antichymotrypsin and al-antitrypsin in adenocarcinomas of the stomach and large intestine. Virchows Arch [A] 1982;398:139–147.

    Google Scholar 

  27. Kittas C, Aroni K, Matani A, Papadimitriou C. Immuno-cytochemical demonstration of al-antitrypsin and al-antichymo-trypsin in human gastrointestinal tract. Hepato-gastroenterology 1982;29:275–277.

    Google Scholar 

  28. Klockars M, Reitamo S. Tissue distribution of lysozyme in man. J Histochem Cytochem 1975;23:932–940.

    Google Scholar 

  29. Saito H, Kasajima T, Masuda A, Imai Y, Ishikawa M. Lysozyme localization in human gastric and duodenal epithelium. Cell Tissue Res 1988;251:307–313.

    Google Scholar 

  30. Vaines K, Brandtzaeg P, Elgjo K, Stave R. Specific and non-specific humoral defense factors in the epithelium of normal and inflamed gastric mucosa. Gastroenterology 1984;86:402–412.

    Google Scholar 

  31. Wittekind C, Wachner R, Henke W, von Kleist S. Localization of CEA, HCG, lysozyme, alpha-1-antitrypsin, and alpha-1-antichymotrypsin in gastric cancer and prognosis. Virchows Arch [A] 1986;409:715–724.

    Google Scholar 

  32. Selested M, Martinez R. Lysozyme: Primary bactericidin in human plasma serum active againstBacillus subtilis. Infect Immun 1978;20:782–791.

    Google Scholar 

  33. Reitamo S, Reitamo J, Sipponen P, Klockars M. The distribution of lysozyme in human gastric mucosa in inflammatory and neoplastic disorders. Acta Pathol Microbiol Scand 1979;87[Sect. A]:451–456.

    Google Scholar 

  34. Erlandsen SL, Parson JA. Immunochemical localization of lysozyme in the small intestine of man using the unlabeled antibody enzyme method. J Histochem Cytochem 1973;21:405–406.

    Google Scholar 

  35. Mason DY, Taylor CR. The distribution of muramidase (lysozyme) in human tissues. J Clin Pathol 1975;28:124–132.

    Google Scholar 

  36. Heitz PU, Wegman W. Identification of neoplastic Paneth cells in an adenocarcinoma of the stomach using lysozyme as a marker, and electron microscopy. Virchows Arch [A] 1980;386:107–116.

    Google Scholar 

  37. Heitz PU, Kasper M, van Norden S, et al. Immunohistochemical localisation of urogastrone to human duodenal and submandibular gland. Gut 1978;19:408–413.

    Google Scholar 

  38. Kasselberg AG, Orth D, Gray M, Stahlman M. Immuno-cytochemical localization of human epidermal growth factor/ urogastrone in several human tissues. J Histochem Cytochem 1985;33:315–322.

    Google Scholar 

  39. Poulsen SS, Nexo E, Skov Olsen P, et al. Immunohistochemical localization of epidermal growth factor in rat and man. Histochemistry 1986;85:389–394.

    Google Scholar 

  40. Elder JB, Ganguli PC, Gillespie IE, et al. Effect of urogastrone on gastric secretion in normal subjects. Gut 1975:16:887–893.

    Google Scholar 

  41. Elder JB, Ganguli PC, Gillespie IE, et al. Effect of urogastrone in the Zollinger-Ellison syndrome. Lancet 1975;II:424–427.

    Google Scholar 

  42. Gillespie IE, Elder JB, Ganguli PC, et al. Initial observations on the inhibitory action of urogastrone on gastric secretory response: in man. Gut 1974;15:337.

    Google Scholar 

  43. Koffman CG, Elder JB, Ganguli PC, et al. Effect of urogastrone on gastric secretion and serum gastrin concentration in patients with duodenal ulceration. Gut 1982;23:951–956.

    Google Scholar 

  44. Konturek SJ, Bielanski W, Konturek JW, et al. Release and action of epidermal growth factor on gastric secretion in humans. Scand J Gastroenterol 1989;24:485–492.

    Google Scholar 

  45. Walker-Smith J. Intravenous epidermal growth factor/urogastrone increases small-intestinal cell proliferation in congenital microvillous atrophy. Lancet 1985:11:1239–1240.

    Google Scholar 

  46. Wright NA, Pike C, Elia G. Ulceration induces a novel epidermal growth factor-secreting cell lineage in human gastrointestinal mucosa. Digestion 1990;46[Suppl 2]:125–133.

    Google Scholar 

  47. Wright NA, Pike C, Elia G. Induction of a novel epidermal growth factor-secreting cell in human gastrointestinal stem cells. Nature 1990;343:82–85.

    Google Scholar 

  48. Cohen S, Carpenter G. Human epidermal growth factor: Isolation and chemical and biological properties. Proc Natl Acad Sci USA 1975;72:1317–1321.

    Google Scholar 

  49. Niinobu T, Ogawa M, Shibata T, et al. Specific binding of human pancreatic secretory trypsin inhibitor to various cultured cells. Res Commun Chem Pathol Pharmacol 1986;53:245–248.

    Google Scholar 

  50. Grossman MI. The glands of Brunner. Physical Rev 1958;38:675–690.

    Google Scholar 

  51. Konturek JW, Bielanski W, Konturek SJ, et al. Distribution and release of epidermal growth factor in man. Gut 1989;30:1194–1200.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bohe, H., Bohe, M., Lindström, C. et al. Pancreatic secretory trypsin inhibitor in human Brunner's glands. J Gastroenterol 30, 90–95 (1995). https://doi.org/10.1007/BF01211381

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01211381

Key words

Navigation